CERE vs. CNX, HCC, ARCH, HNRG, ALNY, TEVA, GMAB, RPRX, BGNE, and BMRN
Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include CNX Resources (CNX), Warrior Met Coal (HCC), Arch Resources (ARCH), Hallador Energy (HNRG), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), and BioMarin Pharmaceutical (BMRN).
CNX Resources (NYSE:CNX) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap oils/energy companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
In the previous week, Cerevel Therapeutics had 5 more articles in the media than CNX Resources. MarketBeat recorded 8 mentions for Cerevel Therapeutics and 3 mentions for CNX Resources. Cerevel Therapeutics' average media sentiment score of 0.60 beat CNX Resources' score of 0.49 indicating that CNX Resources is being referred to more favorably in the media.
95.2% of CNX Resources shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 3.1% of CNX Resources shares are held by company insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CNX Resources has higher revenue and earnings than Cerevel Therapeutics.
CNX Resources has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
CNX Resources received 661 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 70.59% of users gave CNX Resources an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.
CNX Resources has a net margin of 40.44% compared to CNX Resources' net margin of 0.00%. Cerevel Therapeutics' return on equity of 7.68% beat CNX Resources' return on equity.
CNX Resources presently has a consensus target price of $25.00, suggesting a potential downside of 4.94%. Cerevel Therapeutics has a consensus target price of $42.67, suggesting a potential upside of 4.73%. Given CNX Resources' stronger consensus rating and higher possible upside, analysts clearly believe Cerevel Therapeutics is more favorable than CNX Resources.
Summary
CNX Resources beats Cerevel Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Cerevel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cerevel Therapeutics Competitors List
Related Companies and Tools